Page last updated: 2024-09-04

cdri 85-287 and nafoxidine

cdri 85-287 has been researched along with nafoxidine in 1 studies

*Nafoxidine: An estrogen antagonist that has been used in the treatment of breast cancer. [MeSH]

Compound Research Comparison

Studies (cdri 85-287)	Trials (cdri 85-287)	Recent Studies (post-2010) (cdri 85-287)	Studies (nafoxidine)	Trials (nafoxidine)	Recent Studies (post-2010) (nafoxidine)
22	0	3	243	7	3

Protein Interaction Comparison

Protein	Taxonomy	cdri 85-287 (IC50)	nafoxidine (IC50)
Estrogen receptor	Rattus norvegicus (Norway rat)		0.0409
Estrogen receptor beta	Rattus norvegicus (Norway rat)		0.0409

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kon, OL; Ng, SC; Sim, KY; Teo, CC	1

Other Studies

1 other study(ies) available for cdri 85-287 and nafoxidine

Article	Year
Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis. Journal of medicinal chemistry, 1992, Apr-17, Volume: 35, Issue:8 Topics: Benzofurans; Binding Sites; Binding, Competitive; Cell Division; Cell Line; Cholesterol; Estrogen Antagonists; Humans; Ligands; Receptors, Estrogen; Thymidine	1992

Article

Year

Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis.

Journal of medicinal chemistry, 1992, Apr-17, Volume: 35, Issue:8

Topics: Benzofurans; Binding Sites; Binding, Competitive; Cell Division; Cell Line; Cholesterol; Estrogen Antagonists; Humans; Ligands; Receptors, Estrogen; Thymidine

1992